A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

Trial Profile

A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 04 Aug 2017 Planned number of patients changed from 88 to 98.
    • 04 Aug 2017 Planned number of patients changed from 76 to 88.
    • 04 Aug 2017 According to a Sage Therapeutics media release, company now plans to increase expected enrollment to approximately 88 patients with moderate to severe MDD, from approximately 66 patients, due to the robust pace of enrollment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top